Sexually dimorphic effects of ADNP mutation and Davunotide treatment on mice hippocampal transcriptome
ADNP haplo-insufficient (Adnp +/- ) mice or CRSIPR/Cas9 edited to carry the most prevalent neurodevelopmental ADNP syndrome mutation, p.Tyr718*. A subgroup was treated the ADNP fragment, investigational drug, NAP (davunetide). Overall design: RNA was extracted from 2.5-month-old Tyr mouse hippocampi, treated, handled, sequenced on NextSeq500 (Illumina, CA, USA).